Lamberto Andreotti - Bristol Myers Chairman

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>BMY</div>
BMY -- USA Stock  

Fiscal Quarter End: March 31, 2020  

Mr. Lamberto Andreotti is no longer a NonExecutive Chairman of the Board of BristolMyers Squibb Company effective as of May 2nd, 2017. He has served as Executive Chairman of the Board of the Company from May 5, 2015 to August 3, 2015. He is no longer Chief Executive Officer of the Company effective May 5, 2015. He was Chief Executive Officer, Director of BristolMyers Squibb Company. Mr. Andreotti was Chief Executive Officer since May 2010. He was our President and Chief Operating Officer from March 2009 to May 2010. From March 2008 to March 2009, Mr. Andreotti served as Executive Vice President and Chief Operating Officer of BMS. From May 2007 until March 2008, he served as Executive Vice President of BMS and Chief Operating Officer of Worldwide Pharmaceuticals, a division of BMS
Age: 64  Chairman Since 2015      
212 546-4020  www.bms.com
Andreotti served as Executive Vice President of BMS and President of Worldwide Pharmaceuticals from 20052007 and as Senior Vice President and International President of Worldwide Pharmaceuticals from 20022005. He is a member of Pharmaceutical Research and Manufacturers of America and The Business Council.

Lamberto Andreotti Latest Insider Activity

Management Efficiency

The company has 25.8 B in debt with debt to equity (D/E) ratio of 159.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. Bristol Myers Squibb has Current Ratio of 3.8 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


John LechleiterEli Lilly And Company
Kenneth FrazierMerck Company
Ian ReadPfizer
Ashley McEvoyJohnson Johnson
Alex KrauerNovartis AG
Paul BisaroAllergan Plc
Alex GorskyJohnson Johnson
Moncef SlaouiGlaxoSmithKline PLC
Daniel VasellaNovartis AG
Enrico VanniNovartis AG
Ulrich LehnerNovartis AG
Paulus StoffelsJohnson Johnson
Joerg ReinhardtNovartis AG
Jennifer TaubertJohnson Johnson
Joaquin DuatoJohnson Johnson
Brenton SaundersAllergan Plc
Jorge MesquitaJohnson Johnson
Leif JohanssonAstrazeneca PLC
Thibaut MongonJohnson Johnson
Sandra PetersonJohnson Johnson

Company Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange.Bristol Myers Squibb Company (BMY) is traded on BATS Exchange in USA. It is located in 430 E. 29th Street 14th Floor, New York, NY 10016, United States and employs 23,300 people. Bristol Myers is listed under Pharmaceutical Products category by Fama And French industry classification.

Bristol Myers Squibb Leadership Team

Ann Powell, Chief Human Resource Officer, Senior Vice PresidentView
Togo West, Independent DirectorView
Karen Vousden, Independent DirectorView
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics OfficerView
Michael Bonney, DirectorView
Alan Lacy, Independent DirectorView
Robert Bertolini, Independent DirectorView
Jose Baselga, Independent DirectorView
Charles Bancroft, Chief Financial Officer, Executive Vice President - Global Business OperationsView
Gerald Storch, Independent DirectorView
Louis Schmukler, Senior Vice President, President - Global Product Development and SupplyView
Michael Grobstein, Independent DirectorView
Christopher Boerner, Executive Vice President and Chief Commercial OfficerView
Phyllis Yale, DirectorView
John Elicker, Senior Vice President - Corporate Affairs and Investor RelationsView
Anne Nielsen, Senior Vice President Chief Compliance and Ethics OfficerView
Karen Santiago, Senior Vice President, Corporate ControllerView
Giovanni Caforio, Chairman of the Board, Chief Executive OfficerView
Vicki Sato, Lead Independent DirectorView
Emmanuel Blin, Senior Vice President Chief Strategy OfficerView
Joseph Caldarella, Senior Vice President Corporate ControllerView
Julia Haller, DirectorView
Laurie Glimcher, Independent DirectorView
Murdo Gordon, Executive Vice President Chief Commercial OfficerView
Lamberto Andreotti, Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. CommitteeView
Thomas Lynch, Chief Scientific Officer, Executive Vice PresidentView
Lewis Campbell, Independent DirectorView
Dinesh Paliwal, Independent DirectorView
Theodore Samuels, Independent DirectorView
Samuel Moed, Senior Vice President - Strategic Planning and AnalysisView
Matthew Emmens, Independent DirectorView
Ann Judge, Chief Human Resource Officer, Senior Vice PresidentView
Sandra Leung, Executive Vice President, General CounselView
Paul Autenried, Chief Information Officer, Senior Vice PresidentView
Francis Cuss, Executive Vice President Chief Scientific OfficerView
Paul Biondi, Senior Vice President, Head of Strategy & Business DevelopmentView
Kathryn Metcalfe, Executive Vice President - Corporate AffairsView
Peter Arduini, Independent DirectorView

Stock Performance Indicators

Current Sentiment - BMY

Bristol Myers Squibb Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Bristol Myers Squibb Company. What is your opinion about investing in Bristol Myers Squibb Company? Are you bullish or bearish?
98% Bullish
2% Bearish

Bristol Myers Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myers and Johnson Johnson. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.